Find information on thousands of medical conditions and prescription drugs.

Polycythemia vera

Polycythemia is a condition in which there is a net increase in the total circulating erythrocyte (red blood cell) mass of the body. There are several types of polycythemia. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Types

Primary polycythemia (also known as polycythemia vera)

Primary polycythemia, often called polycythemia vera (PCV), polycythemia rubra vera (PRV), erythremia, or just PV, occurs when excess erythrocytes are produced as a result of a proliferative abnormality of the bone marrow. This can also be brought on by abnormalities (tumors) in the kidneys or other growths since the kidney helps to regulate erythrocytes production. Often, excess white blood cells (leukocytosis) and platelets (thrombocytosis) are also produced. It is, therefore, classified as a myeloproliferative disease.

In primary polycythemia there may be 8 to 9 million and occasionally 11 million erythrocytes per cubic millimeter of blood, and the hematocrit may be as high as 70 to 80%. In addition, the total blood volume sometimes increases to as much as twice normal. The entire vascular system can become markedly engorged with blood, and circulation times for blood throughout the body can increase up to twice the normal value. The increased numbers of erythrocytes can increase the viscosity of the blood to as much as five times normal. Capillaries can become plugged by the very viscous blood, and the flow of blood through the vessels tends to be extremely sluggish.

Recently, in 2005, a mutation in the JAK2 kinase (V617F) was found by multiple research groups (Baxter et al., 2005; Levine et al., 2005) to be strongly associated with polycythemia vera. JAK2 is a member of the Janus kinase family. This mutation be helpful in making a diagnosis or as a target for future therapy.

As a consequence of the above, people with untreated PV are at a risk of various thrombotic events (deep venous thrombosis, pulmonary embolism), heart attack and stroke, and have a substantial risk of Budd-Chiari syndrome (hepatic vein thrombosis). The condition is considered chronic; no cure exists. Symptomatic treatment (see below) can normalize the blood count and most patients can live a normal life for years.

Secondary polycythemia

Secondary polycythemia is caused by either appropriate or inappropriate increases in the production of erythropoietin that result in an increased production of erythrocytes. In secondary polycythemia their may be 6 to 8 million and occasionally 9 million erythrocytes per cubic millimeter of blood. A type of secondary polycythemia in which the production of erythropoietin increases appropriately is called physiologic polycythemia. Physiologic polycythemia occurs in individuals living at high altitudes (4275 to 5200 meters), where oxygen availability is less than at sea level. Such people may have 6 to 8 million erythrocytes per cubic millimeter of blood. It is because of this that Lance Armstrong trains in the mountains to prepare for bicycle races.

Read more at Wikipedia.org


[List your site here Free!]


Polycythemia vera
From Gale Encyclopedia of Medicine, 4/6/01 by Rebecca J. Frey

Definition

Polycythemia vera (PV) is a chronic blood disorder marked by an abnormal increase in three types of blood cells produced by bone marrow: red blood cells (RBCs), white blood cells (WBCs), and platelets. PV is called a myeloproliferative disorder, which means that the bone marrow is producing too many cells too quickly. Most of the symptoms of PV are related to the increased volume of the patient's blood and its greater thickness (high viscosity). PV sometimes evolves into a different myeloproliferative disorder or into acute leukemia.

Description

Polycythemia vera is a relatively common progressive disorder that develops over a course of 10-20 years. In the United States, PV affects about one person in every 200,000. PV has several other names, including splenomegalic polycythemia, Vaquez-Osler syndrome, erythremia, and primary polycythemia. Primary polycythemia means that the disorder is not caused or triggered by other illnesses. PV most commonly affects middle-aged adults. It is rarely seen in children or young adults and does not appear to run in families. The male/female ratio is 2:1.

Risk factors for polycythemia vera include:

  • Caucasian race
  • Male sex
  • Age between 40 and 60.

Causes & symptoms

The cause of PV is unknown as of 1998. In general, the increased mass of red blood cells in the patient's blood causes both hemorrhage and abnormal formation of blood clots in the circulatory system (thrombosis). The reasons for these changes in clotting patterns are not yet fully understood.

Early symptoms

The symptoms of early PV may be minimal--it is not unusual for the disorder to be discovered during a routine blood test. More often, however, patients have symptoms that include headaches, ringing in the ears, tiring easily, memory problems, difficulty breathing, giddiness or lightheadedness, hypertension, visual problems, or tingling or burning sensations in their hands or feet. Another common symptom is itching (pruritus). Pruritus related to PV is often worse after the patient takes a warm bath or shower.

Some patients' early symptoms include unusually heavy bleeding from minor cuts, nosebleeds, stomach ulcers, or bone pain. In a few cases, the first symptom is the development of blood clots in an unusual part of the circulatory system (e.g., the liver).

Later symptoms and complications

As the disease progresses, patients with PV may have episodes of hemorrhage or thrombosis. Thrombosis is the most frequent cause of death from PV. Other complications include a high level of uric acid in the blood and an increased risk of peptic ulcer disease. About 10% of PV patients eventually suffer from gout; another 10% develop peptic ulcers.

Spent phase

The spent phase is a development in late PV that affects about 30% of patients. The bone marrow eventually fails and the patient becomes severely anemic, requiring repeated blood transfusions. The spleen and liver become greatly enlarged--in the later stages of PV, the patient's spleen may fill the entire left side of the abdomen.

Diagnosis

Physical examination

PV is often a diagnosis of exclusion, which means that the doctor will first rule out other possible causes of the patient's symptoms. The doctor can detect some signs of the disorder during a physical examination. Patients with PV will have an enlarged spleen (splenomegaly) in 75% of cases. About 50% will have a slightly enlarged liver. The doctor can feel these changes when he or she presses on (palpates) the patient's abdomen while the patient is lying flat. An eye examination will usually reveal swollen veins at the back of the eye. Patients with PV often have unusually red complexions; mottled red patches on their legs, feet, or hands; or swelling at the ends of the fingers.

Diagnostic criteria for PV

Accurate diagnosis of PV is critical because its treatment may require the use of drugs with the potential to cause leukemia. The results of the patient's blood tests are evaluated according to criteria worked out around 1970 by the Polycythemia Vera Study Group. The patient is considered to have PV if all three major criteria are met; or if the first two major criteria and any two minor criteria are met.

Major criteria:

  • Red blood cell mass greater than 36 mL/kg in males, greater than 32 mL/kg in females
  • Arterial oxygen level greater than 92%
  • Splenomegaly.

Minor criteria:

  • Platelet count greater than 400,000/mm3
  • WBC greater than 12,000/mm3 without fever or infection
  • Leukocyte alkaline phosphatase (LAP) score greater than 100 with increased blood serum levels of vitamin B12.

Laboratory testing

Blood tests

The diagnosis of PV depends on a set of findings from blood tests. The most important single measurement is the patient's red blood cell mass as a proportion of the total blood volume. This measurement is made by tagging RBCs with radioactive chromium (51Cr) in order to determine the patient's RBC volume. While a few patients with PV may have a red cell mass level within the normal range if they have had recent heavy bleeding, a high score may eliminate the need for some other tests. A score higher than 36 mL/kg for males and 32 mL/kg for females on the 51Cr test suggests PV. Measurements of the oxygen level in the patient's arterial blood, of the concentration of vitamin B12 in the blood serum, and of leukocyte alkaline phosphatase (LAP) staining can be used to distinguish PV from certain types of leukemia or from other types of polycythemia. LAP staining measures the intensity of enzyme activity in a type of white blood cell called a neutrophil. In PV, the LAP score is higher than normal whereas in leukemia it is below normal.

Bone marrow tests

Bone marrow testing can be used as part of the diagnostic process. A sample of marrow can be cultured to see if red blood cell colonies develop without the addition of a hormone that stimulates RBC production. The growth of a cell colony without added hormone indicates PV. Bone marrow testing is also important in monitoring the progress of the disease, particularly during the spent phase.

Genetic testing

Genetic testing can be used to rule out the possibility of chronic myeloid leukemia. Patients with this disease have a characteristic chromosomal abnormality called the Philadelphia chromosome. The Philadelphia chromosome does not occur in patients with PV.

Imaging studies

Imaging studies are not necessary to make the diagnosis of PV. In some cases, however, imaging studies can detect enlargement of the spleen that the doctor may not be able to feel during the physical examination.

Treatment

Treatment of PV is tailored to the individual patient according to his or her age, the severity of the symptoms and complications, and the stage of the disease.

Phlebotomy

Phlebotomy is the withdrawal of blood from a vein. It is the first line of treatment for patients with PV. Phlebotomy is used to bring down the ratio of red blood cells to fluid volume (the hematocrit) in the patient's blood to a level below 45%. In most cases the doctor will withdraw about 500 mL of blood (about 15 fluid ounces) once or twice a week until the hematocrit is low enough. Phlebotomy is considered the best course of treatment for patients younger than 60 and for women of childbearing age. Its drawback is that patients remain at some risk for either thrombosis or hemorrhage.

Myelosuppression

Myelosuppressive therapies are used to slow down the body's production of blood cells. They are given to patients who are older than 60 and at high risk for thrombosis. These therapies, however, increase the patient's risk of developing leukemia. The substances most frequently used as of 1998 include hydroxyurea (Hydrea), interferon alfa (Intron), or radioactive phosphorus (32P). 32P is used only in elderly patients with life expectancies of less than five years because it causes leukemia in about 10% of patients. Interferon alfa is expensive and causes side effects resembling the symptoms of influenza but is an option for some younger PV patients.

Investigational treatment

The Food and Drug Administration (FDA) has approved the use of anagrelide, an orphan drug, for investigational use in the treatment of PV. Anagrelide has moderate side effects and controls the platelet level in over 90% of patients.

Treatment of complications

The itching caused by PV is often difficult to control. Patients with pruritus are given diphenhydramine (Benadryl) or another antihistamine. Patients with high levels of uric acid are usually given allopurinol (Lopurin, Zyloprim) by mouth. Supportive care includes advice about diet-- splenomegaly often makes patients feel full after eating only a little food. This problem can be minimized by advising patients to eat small meals followed by rest periods.

Because of the clotting problems related to PV, patients should not undergo surgery until their blood counts are close to normal levels. Female patients of childbearing age should be warned about the dangers of pregnancy related to their clotting abnormalities.

Prognosis

The prognosis for untreated polycythemia vera is poor; 50% of patients die within 18 months after diagnosis. Death usually results from heart failure, leukemia, or hemorrhage. Patients being treated for PV can expect to live between 11 and 15 years on average after diagnosis.

Key Terms

Anagrelide
An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Leukocyte alkaline phosphatase (LAP) test
A blood test that measures the level of enzyme activity in a type of white blood cell called neutrophils.
Myeloproliferative disorder
A disorder in which the bone marrow produces too many cells too rapidly.
Myelosuppressive therapy
Any form of treatment that is aimed at slowing down the rate of blood cell production.
Orphan drug
A drug that is known to be useful in treatment but lacks sufficient funding for further research and development.
Philadelphia chromosome
An abnormal chromosome that is found in patients with a chronic form of leukemia but not in PV patients.
Phlebotomy
Drawing blood from a patient's vein as part of diagnosis or therapy. Phlebotomy is sometimes called venesection. It is an important part of the treatment of PV.
Pruritus
An itching sensation or feeling. In PV the itching is not confined to a specific part of the body and is usually worse after a warm bath or shower.
Spent phase
A late development in PV leading to failure of the bone marrow and severe anemia.
Splenomegaly
Abnormal enlargement of the spleen. Splenomegaly is a major diagnostic criterion of PV.

Further Reading

For Your Information

    Books

  • Fruchtman, Steven M. "Polycythemia Vera." In Conn's Current Therapy, edited by Robert E. Rakel. Philadelphia: W. B. Saunders Company, 1998.
  • "Hematology and Oncology: Polycythemia Vera (PV)." In The Merck Manual of Diagnosis and Therapy, vol. II, edited by Robert Berkow, et al. Rahway, NJ: Merck Research Laboratories, 1992.
  • Linker, Charles A. "Blood." In Current Medical Diagnosis & Treatment 1998, edited by Lawrence M. Tierney, Jr., et al. Stamford, CT: Appleton & Lange, 1997.
  • Magalini, Sergio I., et al. Dictionary of Medical Syndromes. Philadelphia: J. B. Lippincott Company, 1990.
  • Physicians' Guide to Rare Diseases, edited by Jess G. Thoene. Montvale, NJ: Dowden Publishing Company, Inc., 1995.
  • "Polycythemia Vera." In Professional Guide to Diseases, edited by Stanley Loeb, et al. Springhouse, PA: Springhouse Corporation, 1991.
  • Silver, Richard T. "Polycythemia Vera and Other Polycythemia Syndromes." In Current Diagnosis 9, edited by Rex B. Conn, et al. Philadelphia: W. B. Saunders Company, 1997.

    Organizations

  • National Organization for Rare Disorders (NORD). P.O. Box 8923, New Fairfield, CT 06812-8923. (800) 999-NORD. (203) 746-6927 (TDD).
  • NIH/National Heart, Lung and Blood Institute. 9000 Rockville Pike, Bethesda, MD 20892-0105. (301) 496-4236.

Gale Encyclopedia of Medicine. Gale Research, 1999.

Return to Polycythemia vera
Home Contact Resources Exchange Links ebay